DNMT1 promotes prostate cancer progression and metastasis by enhancing TRAF6 transcription and facilitating TNF receptor-associated factor 6 (TRAF6)-mediated ubiquitination of EZH2, underscoring its pivotal role in tumorigenesis and potential as a therapeutic target (Li et al., 2022). Here, TRAF6 is linked to prostate carcinoma.